Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p302 | Osteoporosis: evaluation and imaging | ECTS2016

A novel feature selection algorithm based on bone micro architecture analysis to identify osteoarthritis

Ljuhar Richard , Norman Benjamin , Ljuhar Davul , Haftner Tobias , Hladuvka Jiri , Bui Thi Mai Mary , Canhao Helena , MariaRodrigues Ana , Gouveia Nelia , Branco Jaime , Nehrer Stefan , Fahrleitner-Pammer Astrid , Dimai Hans-Peter

Objective: Texture information of the subchondral bone area (SBA) of 2D radiographs represents a promising possibility for evaluating the state of osteoarthritis (OA). However such features are likely to vary within the SBA and therefore the selection of the region of interest (ROI) plays a crucial role. Thus, a feature selection algorithm (FSA) is being applied in order to determine ROIs that enable an optimum discrimination between patients with and without OA.<p class="...

ba0001pp186 | Cell biology: osteoblasts and bone formation | ECTS2013

Involvement of Runx2 in the differentiation process of osteoblastic precursor cells after radiation exposure

Hu Yueyuan , Lau Patrick , Hellweg Christine , Baumstark-Khan Christa , Reitz Guenther

Astronauts on exploratory space missions will experience a complex environment that includes microgravity and radiation. While the deleterious effects of unloading on bone are well established, fewer studies have focused on the effects of radiation. Space radiation produces distinct biological damages which, up to now, little is known about the correlation between radiation exposure and bone tissue. In our study we used osteoblastic precursor cells to investigate the radiation...

ba0002p31 | (1) | ICCBH2013

Craniofacial consequences of high dose zoledronic acid injections in onco-pediatric patients

Lezot Frederic , Chesneau Julie , Battaglia Severine , Brion Regis , Farges Jean-Christophe , Heymann Dominique , Redini Francoise

Background: High doses of zoledronic acid (ZOL), one of the most potent inhibitors of bone resorption; is currently evaluated in a phase III clinical trial in Europe for the treatment of malignant pediatric primary bone tumors. The impact of such an intensive treatment on the craniofacial skeleton is a critical question in the context of patients with actively growing skeleton; in particular in the light of our previous studies evidencing that endochondral bone formation was t...

ba0005p474 | Paediatric bone disease | ECTS2016

Defining a new severity classification and searching for a pronostic factor in cherubism: NFATc1 localization is the answer

Kadlub Natacha , Siessecq Quentin , Galmiche Louise , Vazquez Marie-Paule , Badoual Cecile , Berdal Ariane , Picard Arnaud , Descroix Vianney , Coudert Amelie

Cherubism is a rare genetic disease (OMIM #118400) characterized by a massive jaw bone osteolysis. This pathology appears around 2–5 years old and in the less severe cases spontaneously regresses after puberty. So far the only treatment available is surgery, often disabling and traumatic. As the cherubism pathophysiology is not yet understood, we carried out a thoroughly characterization of the cherubism granulomas from ten unrelated patients to determine the cells involv...

ba0001pp434 | Osteoporosis: treatment | ECTS2013

Bone histology and histomorphometry: effects of 5 years of denosumab in the FREEDOM Extension

Brown Jacques P , Wagman Rachel , Dempster David W , Kendler David , Miller Paul , Bolognese Michael , Valter Ivo , Beck Jensen Jens-Erik , Zerbini Cristiano , Zanchetta Jose R , Daizadeh Nadia , Reid Ian

DMAb increases BMD and reduces bone resorption and risk of vertebral, nonvertebral and hip fractures in women with PMO. Transiliac crest bone biopsies in 47 subjects treated with DMAb for 1–3 years showed reduced bone turnover vs 45 Pbo-treated subjects, which reversed on treatment cessation. Since bone turnover reduction is sustained and fracture incidence low over 6 years’ DMAb treatment, we evaluated DMAb’s effects on tissue-level remodelling in the FREEDOM E...

ba0004p106 | (1) | ICCBH2015

Metatropic dysplasia is associated with increased fracture risk and increased markers of bone turnover

Bober Michael , Duker Angela , Carney Megan , Ditro Colleen , Rogers Kenneth , Mackenzie William

Metatropic dysplasia (MD) was first described by Maroteaux et al. in 1966. Its name was derived from the Greek word metatropos which means ‘changing pattern’ because individuals with this diagnosis begin life with a short-limbed dysplasia and a long trunk with narrow chest, and over time their dysplasia becomes short-trunked due to progressive kyphoscoliosis1. It is now recognized that MD is caused by gain-of-function mutations in transie...

ba0004p120 | (1) | ICCBH2015

Fracture incidence and bisphosphonate therapy in boys with Duchenne Muscular Dystrophy

Crabtree Nicola , Hogler Wolfgang , Sahota Jaskiran , Chapman Dee , Walford Jacky , Roper Helen , Willis Tracy , Shaw Nicholas

Background: DMD is a progressive neuromuscular disease often treated with oral glucocorticoids (GC) to prolong ambulation and maintain cardiovascular function. However, the osteotoxic GC effects often result in a skeleton prone to fractures. DMD boys presenting with fractures are treated with bisphosphonates (BP) but evidence of beneficial effects is limited. The aim of this work was to review the use of intravenous BPs in a group of severely affected boys with fractures.<...

ba0004p169 | (1) | ICCBH2015

Comparison of the response to bisphosphonate treatment between acute lymphoblastic leukaemia and osteogenesis imperfecta type I

Kumaran Anitha , Uday Suma , Ginige Nimasari , Sakka Sophia , Saraff Vrinda , Sahota Jaskiran , Crabtree Nicola , Shaw Nick , Hogler Wolfgang

Background: Osteoporosis in children with osteogenesis imperfecta (OI) type 1 and acute lymphoblastic leukaemia (ALL) is characterised by high bone turnover. However the ability of spontaneous healing and reshaping of bone is retained in ALL even in the absence of bisphosphonate (BP) therapy, but impaired in OI.Aim: To compare the response to BP therapy in children with ALL and OI.Methods: Retrospective case note review of children...

ba0005p212 | Chondrocytes and cartilage | ECTS2016

Histological structure of the mandibular condylar cartilage in rats of various age after 60-day intake of epichlorohydrin

Gavrilov Vladimir , Luzin Vladyslav , Kozhemyaka Ida , Mishchenko Nina

Objectives: This study is aimed at investigating of histological features of mandibular condylar cartilage (MCC) in rats after 2-month inhalation of epichlorohydrin (ECh) vapors and administration of thiotriazoline (Th) and Echinaceae tinctura (ET) as medication.Methods: The experiment involved 420 male rats (young, adult and senile). The animals were split into the groups: 1st group comprised control animals, the 2nd group comprised the animals...

ba0005p452 | Other diseases of bone and mineral metabolism | ECTS2016

Micro-RNA expression profiling in Paget’s disease of bone

Bianciardi Simone , Merlotti Daniela , Sebastiani Guido , Valentini Marco , Gonnelli Stefano , Caffarelli Carla , Evangelista Isabella Anna , Cenci Simone , Nuti Ranuccio , Dotta Francesco , Gennari Luigi

Since their initial discovery, microRNAs (miRNAs) have emerged as critical post-transcriptional regulators of gene expression that are able to modulate bone remodeling. Nonetheless, despite the peculiar and aggressive phenotype of pagetic osteoclasts and the associated increase in osteoblast activity, whether deregulation of miRNAs is involved in Paget’s disease of bone (PDB) remains unknown. Here, we performed a serum miRNA expression profile (Taqman Human MicroRNA Array...